Rohm & Haas innovations will reduce time to market and formulation costs

A new line of patented technologies that will reduce time to market and enable pharmaceutical manufacturers to save formulation costs has been launched by Rohm & Haas. Advanced Release Technologies (ART) incorporate some of the company's most widely used excipients, and make use of Rohm & Haas's expertise to exploit their in-built functionality. ART is based around functional polymers and key applications of the technologies will include their use as active ingredients and excipients, in taste-masking, tablet disintegration, sustained release and drug stabilisation.

Rohm & Haas has also launched Ambersynth CTC solid phase resin, which has been specifically designed and optimised to produce therapeutic peptides. Said to perform equally well when scaled up as in research protocols, it was developed in response to demand from manufacturers, notably in the biopharmaceutical sector, for high standards of consistency and control in their production processes.

Ambersynth CTC is said to show consistently high loading efficiencies and post-cleavage recovery rates. Rohm & Haas has used its expertise in polymer chemistry to make a consistent, homogeneous resin that remains consistent in use, offering higher yield, faster reaction kinetics and reduced cycle times. These savings could now make viable some products that were previously considered uneconomic, the company says.